FDA warns Taiwans Visgeneer, Inc., about Quality System and Medical Device Reporting violations in its manufacturing of blood glucose and blood uric a...
FDA issues an online post describing the safety to patients of the type of PFAS used in medical devices.
FDA accepts for priority review a Bristol Myers Squibb supplemental BLA for Breyanzi (lisocabtagene maraleucel; liso-cel) as a potential treatment for...
FDA accepts a Lantheus NDA for a new formulation of its Pylarify F 18 prostate-specific membrane antigen imaging agent.
FDA publishes the FY 2025 Quarter 2 update to the CBER/CDER Data Standards Program Action Plan.
FDA grants Clarametyx Biosciences both fast track and qualified infectious disease product designations for its lead therapeutic candidate, CMTX-101, ...
FDA warns Italys Mectronic Medicale about Quality System, Medical Device Reporting, and other violations in its illegal manufacturing and marketing of...
FDAs Oncology Center of Excellence announces a two-day virtual public workshop to advance the development of patient registries in oncology, with a fo...